Cargando…

Development and External Validation of a Novel Model for Predicting Postsurgical Recurrence and Overall Survival After Cytoreductive R0 Resection of Epithelial Ovarian Cancer

PURPOSE: Treatment of epithelial ovarian cancer is evolving towards personalization and precision, which require patient-specific estimates of overall survival (OS) and progression-free survival (PFS). PATIENTS AND METHODS: Medical records of 1173 patients who underwent debulking surgery in our cent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Qiaqia, Deng, Yinghong, Wei, Wei, Yang, Fan, Lin, An, Yao, Desheng, Zhu, Xiaofeng, Li, Jundong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984120/ https://www.ncbi.nlm.nih.gov/pubmed/35402239 http://dx.doi.org/10.3389/fonc.2022.859409

Ejemplares similares

Hepatic Hilar Lymph Node Resection in Cytoreductive Surgery for Advanced Ovarian Cancer: A Necessity or Not?
por: Huang, Honglian, et al.
Publicado: (2021)

Prediction Models for Complete Resection in Secondary Cytoreductive Surgery of Patients With Recurrent Ovarian Cancer
por: Jiang, Caixia, et al.
Publicado: (2021)

Feasibility of laparoscopic cytoreduction in patients with localized recurrent epithelial ovarian cancer
por: Paik, E Sun, et al.
Publicado: (2016)

Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection
por: Onda, T, et al.
Publicado: (2005)

Hepatobiliary Disease Resection in Patients with Advanced Epithelial Ovarian Cancer: Prognostic Role and Optimal Cytoreduction
por: Di Donato, Violante, et al.
Publicado: (2020)

Liver Resection as Part of Cytoreductive Surgery for Ovarian Cancer
por: Luna-Abanto, Jorge, et al.
Publicado: (2020)

Narrow-Margin Hepatectomy Resulted in Higher Recurrence and Lower Overall Survival for R0 Resection Hepatocellular Carcinoma
por: Liu, Lihong, et al.
Publicado: (2021)

Splenectomy during cytoreductive surgery in epithelial ovarian cancer
por: Sun, Hengzi, et al.
Publicado: (2018)

Tertiary cytoreduction in the setting of recurrent ovarian cancer (Review)
por: DOGAN, NASUH UTKU, et al.
Publicado: (2013)

Minimally-Invasive Secondary Cytoreduction in Recurrent Ovarian Cancer
por: Certelli, Camilla, et al.
Publicado: (2023)

The current role of secondary cytoreductive surgery for recurrent ovarian cancer
por: de Bree, Eelco, et al.
Publicado: (2022)

Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer
por: Wei, Wei, et al.
Publicado: (2022)

Artificial intelligence weights the importance of factors predicting complete cytoreduction at secondary cytoreductive surgery for recurrent ovarian cancer
por: Bogani, Giorgio, et al.
Publicado: (2018)

Simplified Selection Criteria for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer
por: Son, Joo-Hyuk, et al.
Publicado: (2022)

The value of PET/CT for cytoreductive surgery selection in recurrent ovarian carcinoma
por: Nunes, Rafael Leite, et al.
Publicado: (2023)

EFHD2 promotes epithelial-to-mesenchymal transition and correlates with postsurgical recurrence of stage I lung adenocarcinoma
por: Fan, Chi-Chen, et al.
Publicado: (2017)

Development and Validation of Nomograms to Predict Overall Survival Outcomes in Serous Ovarian Cancer Patients with Satisfactory Cytoreductive Surgery and Chemotherapy
por: Liu, Yuan-Yuan, et al.
Publicado: (2022)

Platinum resistant recurrence and early recurrence in a multi-centre cohort of patients undergoing interval cytoreductive surgery for advanced epithelial ovarian cancer
por: Bhatt, Aditi, et al.
Publicado: (2022)

Cytoreductive surgery in ovarian cancer
por: Pomel, Christophe, et al.
Publicado: (2007)

Can primary optimal cytoreduction be predicted in advanced epithelial ovarian cancer preoperatively?
por: Mousavi, Azam-Sadat, et al.
Publicado: (2010)

The role of CA-125, GLS and FASN in predicting cytoreduction for epithelial ovarian cancers
por: Winarno, G. N. A., et al.
Publicado: (2020)

External validation of three prognostic models for overall survival in patients with advanced-stage epithelial ovarian cancer
por: van de Laar, R, et al.
Publicado: (2014)

Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer
por: Xu, Xia, et al.
Publicado: (2013)

Which patients benefit from secondary cytoreductive surgery in recurrent ovarian cancer?
por: Zang, Rongyu, et al.
Publicado: (2019)

Survival impact of bowel resection at the time of interval cytoreductive surgery for advanced ovarian cancer
por: McNamara, Blair, et al.
Publicado: (2021)

Repeat cytoreductive surgery with or without intraperitoneal chemotherapy for recurrent epithelial appendiceal neoplasms
por: Karpes, J. B., et al.
Publicado: (2020)

Distal pancreatectomy with splenectomy for the management of splenic hilum metastasis in cytoreductive surgery of epithelial ovarian cancer
por: Xiang, Libing, et al.
Publicado: (2016)

Prognostic Value of Preoperative Serum Carcinoembryonic Antigen for Overall Survival and Recurrence-Free Survival in Resectable Thymic Epithelial Tumors
por: Huang, Yang-Yu, et al.
Publicado: (2022)

Long term survival of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in advanced epithelial ovarian cancer
por: Zhang, Jue, et al.
Publicado: (2021)

Mininvasive Cytoreduction Surgery plus HIPEC for Epithelial Ovarian Cancer: A Systematic Review
por: Ronsini, Carlo, et al.
Publicado: (2023)

External Validation of the Cancer of the Prostate Risk Assessment Postsurgical Score for Prediction of Disease Recurrence after Radical Prostatectomy
por: Yıkılmaz, Taha Numan, et al.
Publicado: (2016)

Evaluation of Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Stage III Epithelial Ovarian Cancer
por: Lei, Ziying, et al.
Publicado: (2020)

Publisher Correction: EFHD2 promotes epithelial-to-mesenchymal transition and correlates with postsurgical recurrence of stage I lung adenocarcinoma
por: Fan, Chi-Chen, et al.
Publicado: (2018)

Update on the secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a narrative review
por: Conte, Carmine, et al.
Publicado: (2021)

Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer
por: Zou, Ruoyao, et al.
Publicado: (2023)

A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery: predictors- and nomogram-based analyses
por: Bogani, Giorgio, et al.
Publicado: (2018)

En-bloc rectosigmoid and mesorectum resection as part of pelvic cytoreductive surgery in advanced ovarian cancer
por: Alcazar, Juan Luis, et al.
Publicado: (2020)

Weekly induction intraperitoneal chemotherapy after primary surgical cytoreduction in patients with advanced epithelial ovarian cancer
por: Yu Zang, Rong, et al.
Publicado: (2006)

Targeted Muscle Reinnervation Does Not Increase the Risk of Postsurgical Complication or Overall Cost
por: Deeyor, Sorka T., et al.
Publicado: (2022)

Changes in peripheral lymphocyte populations in patients with advanced/recurrent ovarian cancer undergoing splenectomy during cytoreductive surgery
por: Chen, Wei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lk79psj56309g5o1854942aomh